Skip To Main Content

Search

For optimal search results, please limit to 2 product keywords

If you are searching for information related to a product:

  • For optimal results, please enter at least 2 search terms in addition to product name
  • Example: [product name] [search term] [search term]
  • Example: Product + clinical trials
  • For an exact match, please include search terms in double quotations. For example: "Elevatum"

Pipeline & Clinical Trials

Explore the investigational molecules and recruiting clinical trials in our pipeline.

The clinical trials and molecule information included represent only a subset of the Roche/Genentech pipeline, specifically highlighting a selection of investigational molecules involved in actively recruiting Phase 3 trials. For a comprehensive overview of our full development portfolio or all actively recruiting Phase 3 trials, please visit genentech-clinicaltrials.com.

Clipboard with checklist icon

Recruiting Trials

Explore select clinical trials that are actively recruiting participants. To view all clinical trials related to a molecule, go to the section below.

Phase II: CT-996 in Obesity or Overweight (Study BP45702)

This multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of RO7795081 for chronic weight management in adult participants with obesity or overweight with at least one weight-related comorbidity, but without diabetes mellitus.

Phase II: Emugrobart for Obesity or Overweight (GYMINDA study)

The Phase 2 GYMINDA study is a study to assess efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of Emugrobart (RO7204239) in combination with Tirzepatide in participants who are obese or overweight with at least one weight-related comorbidity.

Molecule icon

Molecules

Explore our investigational molecules by phase. View individual molecules to explore all clinical trials related to that molecule.

Molecule Disease State Modality
CT-388 (RG6640) Type 2 Diabetes, Obesity Biased dual GLP-1/GIP receptor agonist View Molecule

View Clinical Trials

CT-996 (RG6652) Type 2 Diabetes, Overweight or Obesity GLP-1 receptor agonist View Molecule

View Clinical Trials

Emugrobart (RG6237) Type 2 Diabetes, Overweight or Obesity, SMA, FSHD Anti-latent myostatin View Molecule

View Clinical Trials

These compounds and their uses are investigational and have not been approved by the U.S. Food and Drug Administration. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.

Search Medical Information

Search by keyword across all molecules and clinical trials.

Looking for more information?

Reach out to a Genentech Medical Science Liaison near you, or connect with the contact center.

Call the Trial Information Support Team: 1-888-662-6728 Hours: Monday-Friday, 5am-5pm PT